Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/52570
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBourdin A.-
dc.contributor.authorBardin P.-
dc.contributor.authorChanez P.-
dc.date.accessioned2024-10-16T01:56:20Z-
dc.date.available2024-10-16T01:56:20Z-
dc.date.copyright2024-
dc.date.issued2024-09-30en
dc.identifier.citationExpert Review of Respiratory Medicine. 18(8) (pp 561-567), 2024. Date of Publication: 2024.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/52570-
dc.description.abstractIntroduction: There are no validated decision-making algorithms concerning severe asthma (SA) management. Future risks are crucial factors and can be derived from SA trajectories. Areas covered: The future severe asthma-decision trees should revisit current knowledge and gaps. A focused literature search has been conducted. Expert opinion: Asthma severity is currently defined a priori, thereby precluding a role for early interventions aiming to prevent outcomes such as exacerbations (systemic corticosteroids exposure) and lung function decline. Asthma 'at-risk' might represent the ultimate paradigm but merits longitudinal studies considering modern interventions. Real exacerbations, severe airway hyperresponsiveness, excessive T2-related biomarkers, noxious environments and patient behaviors, harms of OCS and high-doses inhaled corticosteroids (ICS), and low adherence-to-effectiveness ratios of ICS-containing inhalers are predictors of future risks. New tools such as imaging, genetic, and epigenetic signatures should be used. Logical and numerical artificial intelligence may be used to generate a consistent risk score. A pragmatic definition of response to treatments will allow development of a validated and applicable algorithm. Biologics have the best potential to minimize the risks, but cost remains an issue. We propose a simplified six-step algorithm for decision-making that is ultimately aiming to achieve asthma remission.Copyright © 2024 Informa UK Limited, trading as Taylor & Francis Group.-
dc.publisherTaylor and Francis Ltd.-
dc.relation.ispartofExpert Review of Respiratory Medicine-
dc.subject.meshartificial intelligence-
dc.subject.meshdrug megadose-
dc.subject.meshepigenetics-
dc.subject.meshgenetics-
dc.subject.meshlung function-
dc.subject.meshrespiratory tract allergy-
dc.subject.meshsevere asthma-
dc.titleImagining the severe asthma decision trees of the future.-
dc.typeArticle-
dc.identifier.affiliationRespiratory and Sleep Medicine-
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1080/17476348.2024.2390987-
dc.publisher.placeUnited Kingdom-
dc.identifier.pubmedid39120156 [https://www.ncbi.nlm.nih.gov/pubmed/?term=39120156]-
dc.identifier.institution(Bourdin) Departement de Pneumologie et Addictologie, PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, France-
dc.identifier.institution(Bardin) Monash Lung and Sleep Allergy Immunology, Monash Hospital, Monash Health and University, Hudson Institute, Melbourne, VIC, Australia-
dc.identifier.institution(Chanez) APHM, Clinique des bronches allergies et sommeil, Marseille, France-
dc.identifier.institution(Chanez) Aix Marseille Univ, INSERM U1263, INRA 1260 (C2VN), Marseille, France-
dc.identifier.affiliationmh(Bardin) Monash Lung and Sleep Allergy Immunology, Monash Hospital, Monash Health and University, Hudson Institute, Melbourne, VIC, Australia-
item.openairetypeArticle-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
crisitem.author.deptRespiratory and Sleep Medicine-
Appears in Collections:Articles
Show simple item record

Page view(s)

4
checked on Oct 23, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.